Last $1.35 USD
Change Today -0.01 / -0.74%
Volume 54.7K
SNGX On Other Exchanges
As of 3:57 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

soligenix inc (SNGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/14 - $2.50
52 Week Low
10/14/14 - $1.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SOLIGENIX INC (SNGX)

Related News

No related news articles were found.

soligenix inc (SNGX) Related Businessweek News

No Related Businessweek News Found

soligenix inc (SNGX) Details

Soligenix, Inc., a clinical stage biopharmaceutical company, is engaged in developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and various biodefense vaccines and therapeutics. The company operates in, BioTherapeutics and Vaccine/Biodefense. The BioTherapeutics segment develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease, acute radiation enteritis, and chronic graft-versus-host disease, as well as novel innate defense regulator technology for the treatment of oral mucositis. The Vaccines/BioDefense segment offers RiVax, a ricin toxin vaccine; VeloThrax, an anthrax vaccine; OrbeShield, a gastrointestinal acute radiation syndrome program; and SGX943, a melioidosis therapeutic. These vaccine programs are supported by the company’s heat stabilization technology, known as ThermoVax. The company has collaboration with Intrexon Corporation to focus on the joint development of a treatment for Melioidosis, a high priority biothreat and an area of unmet medical need. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

17 Employees
Last Reported Date: 11/17/14
Founded in 1987

soligenix inc (SNGX) Top Compensated Officers

Chairman, Chief Execdutive Officer and Presid...
Total Annual Compensation: $641.0K
Acting Chief Financial Officer, Vice Presiden...
Total Annual Compensation: $276.0K
Compensation as of Fiscal Year 2013.

soligenix inc (SNGX) Key Developments

Soligenix Appoints Oreola Donini as Senior Vice President and Chief Scientific Officer

Soligenix, Inc. announced the appointment of Oreola Donini, PhD, as Senior Vice President & Chief Scientific Officer replacing Robert Brey, PhD, who is no longer employed with the Company. Dr. Donini previously held the position of Vice President, Preclinical Research and Development since joining Soligenix on August 15, 2013. Dr. Donini has worked previously with ESSA Pharma Inc.

Soligenix, Inc. Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

Soligenix, Inc. announced financial results for the third quarter and nine months ended September 30, 2014. The company's revenues were $2.8 million as compared to $0.3 million for the quarter a year ago. Net loss was $4.3 million, or $0.21 per share, as compared to $6.6 million, or $0.34 per share a year ago. The company's revenues were $5.1 million as compared to $1.8 million for the nine months of 2013. For the nine months ended September 30, 2014 as compared to September 30, 2013, revenues increased $3.3 million primarily related to contracts with the US Department of Health and Human Service's Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) in support of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or BDP) development in the treatment of gastrointestinal acute radiation syndrome (GI ARS). Net loss was $8.6 million, or $0.43 per share as compared to $11.1 million, or $0.78 a year ago.

Soligenix, Inc. Appoints Rasappa Arumugham as Vice President of Biopharmaceutical Development

Soligenix, Inc. announced that it has appointed Rasappa Arumugham, PhD, as its Vice President of Biopharmaceutical Development. Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development (R&D) in the areas of formulation research, analytical method development, quality control (QC), and manufacturing. He has a proven track record in development, scale-up, and technology transfer supporting commercialization of vaccines and biologics, including Prevnar(R), Tetramune(TM), HibTITER(R), Meningitec(R) Conjugate and meningitis B (bivalent rLP2086) Lipoprotein Subunit Vaccines. Most recently, Dr. Arumugham served as the Head of Microbial Vaccines Analytics at Merck's Manufacturing Division.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNGX:US $1.35 USD -0.01

SNGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNGX.
View Industry Companies

Industry Analysis


Industry Average

Valuation SNGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOLIGENIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at